Abstract
A second allogeneic (allo) hematopoietic cell transplant (HCT) is an important therapeutic consideration for patients relapsing after their first. We conducted a retrospective review of 41 pediatric patients with leukemia that underwent a second allo-HCT at our institution. Overall, 53.7 and 43.9 % of patients were alive and disease-free at 1 and 5 years, respectively, after the second allo-HCT. The factors affecting outcome by both univariate and multivariate analysis were interval between transplants and the use of a myeloablative conditioning (MAC) regimen prior to second transplant. Outcomes were inferior in patients who received their second transplant <6 months from their first HCT when compared to patients in whom the interval between HCTs was 6-12 or more than 12 months. Interval between HCTs was also significant when each type of leukemia (acute lymphoblastic leukemia (ALL) n = 21, acute myelogenous leukemia (AML) n = 11, and chronic myelogenous leukemia (CML) n = 7) was analyzed separately. In univariate analysis, use of the same donor and use of a matched sibling donor resulted in significant improved outcome. There was not a significant association between disease-free survival (DFS) and age, remission status, use o...Continue Reading
References
Dec 1, 1991·British Journal of Haematology·A J BarrettF E Zwaan
Nov 1, 1988·British Journal of Haematology·F FrassoniA Gratwohl
Feb 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J P RadichJ A Hansen
Jul 1, 1997·Bone Marrow Transplantation·J MehtaS Singhal
Jun 28, 2003·Pediatrics International : Official Journal of the Japan Pediatric Society·Keiichi IsoyamaUNKNOWN Kanagawa Cord Blood Bank
Dec 4, 2003·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Soheil MeshinchiJean E Sanders
Jun 19, 2004·Hematology·F Al-QurashiM Aljurf
Jun 15, 2005·British Journal of Haematology·Kazuhiko KobayashiUNKNOWN Tokyo SCT Consortium Institution
Oct 24, 2007·Bone Marrow Transplantation·B E Shaw, N H Russell
Mar 17, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Meirav KedmiMichael Y Shapira
Mar 18, 2009·International Journal of Hematology·M OdaS Kato
Nov 19, 2010·Expert Review of Hematology·A John Barrett, Minoo Battiwalla
Mar 1, 2012·Bone Marrow Transplantation·M KatoK Kato
May 1, 2012·Pathology Oncology Research : POR·Ryo HanajiriHideki Akiyama
Nov 7, 2012·Bone Marrow Transplantation·R BajwaH Frangoul
Jul 28, 2013·Journal of Pediatric Hematology/oncology·Hee Won ChuehHong Hoe Koo
Mar 15, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Swati NaikRobert Krance
Citations
Jan 28, 2017·Immunotherapy·Faiz AnwerIrbaz Bin Riaz
Feb 11, 2020·Leukemia & Lymphoma·Volkan HazarSerap Aksoylar
Feb 6, 2020·British Journal of Haematology·Theodor UdenMartin G Sauer
Dec 2, 2017·British Journal of Haematology·Michaela KuhlenChristina Peters
Jan 24, 2019·Bone Marrow Transplantation·Ann DahlbergAnn Woolfrey
Dec 16, 2020·Pediatric Transplantation·Volkan HazarUNKNOWN Turkish Pediatric Bone Marrow Transplantation Study Group
Mar 21, 2021·Bone Marrow Transplantation·Akshay SharmaBrandon M Triplett
Aug 10, 2021·Oncoimmunology·Holly PariuryEmmanuel Katsanis
Nov 26, 2021·International Journal of Hematology·Shogo KobayashiAtsushi Kikuta